5,689 trials (keyword fallback)
Acute Coronary Syndrome
Primary: Time to First Occurence of Primary CV Event: CV Death, Non-Fatal MI, Non-Fatal Stroke or Hospitalization for Unstable Angina — 399; 406 participants — p=0.8542
Idiopathic Pulmonary Fibrosis
Primary: Absolute Change in Percent Predicted Forced Vital Capacity (FVC) — -8.0; -10.0; -12.4 Change in Percent Predicted FVC
Idiopathic Pulmonary Fibrosis · Cough
Primary: Efficacy of Thalidomide in Suppressing the Chronic Cough of Idiopathic Pulmonary Fibrosis Using the Cough Quality of Life Questionnaire. — 47.3; 55.2; 61.6; 44.5 units…
Atherosclerotic Cardiovascular Disease
Primary: Time to First Occurrence of Major Adverse Cardiovascular Event (MACE); Percentage of Observed Participants With Outcome Measure Events During the Study — 11.1; 9.5…
Long COVID
Primary: Change in the Symptoms of Long COVID-19 Patients — 20.33; 27; 15.71; 22.43 units on a scale — p=0.200
Hypertension, Pulmonary · Altitude Sickness
Primary: Mean Pulmonary Artery Pressure — 16.8667; 15.6545; 16.3800; 16.6833 mm Hg
Idiopathic Pulmonary Fibrosis · Pulmonary Fibrosis
Primary: Percentage of Participants With a Treatment-Emergent Adverse Event (AE), Serious AE (SAE), Severe AE, Life-threatening AE, Death or Discontinuation Because of an AE…
Chronic Hepatitis C Infection
Primary: Safety of Fuzheng Huayu Treatment in Chronic Hepatitis C Subjects Who Have Failed Prior Anti-HCV Therapy or Cannot Receive or Refused Interferon Based Therapy. — 55; 55…
Pulmonary Fibrosis
Primary: Annual Rate of Decline in Forced Vital Capacity (FVC) — -129.0; -137.5; -132.9 milliliters per year (mL/ yr)
Idiopathic Pulmonary Fibrosis
Primary: Forced Vital Capacity (FVC) at Baseline and End of Period 1 — 2.74; 2.83; 2.40; 2.57 litres — p=0.9631
Precancerous Condition
Primary: Number of Participants With Stable or Improved Forced Vital Capacity (FVC) Response at 1 Year — 7; 5; 5 Participants
Idiopathic Pulmonary Fibrosis
Primary: Absolute Change in Percent Predicted Forced Vital Capacity(FVC) — -9; -10 Change in Percent Predicted FVC
Idiopathic Pulmonary Fibrosis
Primary: Change in Percent Predicted Forced Vital Capacity (%FVC) From Baseline to Week 52 — 16.5; 31.8; 22.7; 9.7 percentage of patients
Idiopathic Pulmonary Fibrosis
Primary: Extent of Exposure to Bosentan in Patients With Idiopathic Pulmonary Fibrosis (IPF) — 6.4 months
Pulmonary Fibrosis
Primary: Cough Count Per Hour (CC/hr) Measured Over a 24-hour Period at Baseline Visit, Week 4, Week 8, and at Day 82 — 10.79; 12.63; 10.36; 12.45 Cough count per hour